7 |
Krystel-Whittemore M, Xu J, Brogi E, et al. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy [J]. Breast Cancer Res Treat, 2019, 177(1): 61-66.
|
8 |
Xu B, Shen JG, Zhang LW, et al. HER2 protein expression level is positively associated with the efficacy of neoadjuvant systemic therapy in HER2-positive breast cancer [J]. Pathol Res Pract, 2022, 234: 153900.
|
9 |
马祥敏, 张香梅, 周新平, 等. 曲妥珠单抗和帕妥珠单抗联合化疗对HER2阳性乳腺癌新辅助治疗的真实世界研究 [J]. 肿瘤防治研究, 2022, 49(1): 46-52.
|
10 |
刘建兰, 陈黛诗, 胡泓, 等. HER2阳性浸润性乳腺癌新辅助治疗反应的预测因子及治疗前后HER2状态变化的评估 [J]. 中国癌症杂志, 2022, 32(5): 417-426.
|
11 |
Katayama A, Miligy IM, Shiino S, et al. Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer [J]. Mod Pathol, 2021, 34(7): 1271-1281.
|
12 |
Wang Y, Singh K, Dizon D, et al. Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer [J]. Breast Cancer Res Treat, 2021, 186(3): 667-676.
|
13 |
《乳腺癌HER2检测指南(2019版)》编写组. 乳腺癌HER2检测指南(2019版) [J]. 中华病理学杂志, 2019, 48(3): 169-175.
|
14 |
《乳腺癌雌、孕激素受体检测指南》编写组. 乳腺癌雌、孕激素受体检测指南 [J]. 中华病理学杂志, 2015, 44(4): 237-240.
|
15 |
Horimoto Y, Ishizuka Y, Ueki Y, et al. Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients [J]. BMC Cancer, 2022, 22(1): 242.
|
16 |
Giuliani S, Ciniselli CM, Leonardi E, et al. In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/HER2 amplified cases [J]. Virchows Arch, 2016, 469(1): 45-50.
|
17 |
Onsum MD, Geretti E, Paragas V, et al. Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients [J]. Am J Pathol, 2013, 183(5): 1446-1460.
|
18 |
Eirini T, Leila K, Morena C, et al. Therapeutic strategies for the management of hormone receptor- positive, human epidermal growth factor receptor 2-positive (HR +/HER2+) breast cancer:A review of the current literature [J]. Cancer, 2020, 12(11): 3317.
|
19 |
Perez EA, Reinholz MM, Hillman DW, et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial [J]. J Clin Oncol, 2010, 28(28): 4307-4315.
|
20 |
Liu Z, Wang C, Chen X, et al. Pathological response and predictive role of tumour- infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial [J]. Eur J Cancer, 2022, 165: 157-168.
|
21 |
Yin W, Wang Y, Wu Z, et al. Neoadjuvant trastuzumab and pyrotinib for locally advanced HER2-positive breast cancer (NeoATP): primary analysis of a phase II study [J]. Clin Cancer Res, 2022, 28(17): 3677-3685.
|
22 |
Wu J, Jiang Z, Liu Z, et al. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial [J]. BMC Med, 2022, 20(1): 498.
|
23 |
Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer [J]. N Engl J Med, 2022, 387(1): 9-20.
|
1 |
Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial [J]. Lancet Oncol, 2012, 13(1): 25-32.
|
2 |
Shao Z, Pang D, Yang H, et al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial [J]. JAMA Oncol, 2020, 6(3): e193692.
|
3 |
van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial [J]. Lancet Oncol, 2018, 19(12): 1630-1640.
|
4 |
Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) [J]. Ann Oncol, 2013, 24(9): 2278-2284.
|
5 |
Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial [J]. The Lancet Oncology, 2018, 19(1): 115-126.
|
6 |
Swain SM, Ewer MS, Viale G, et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study [J]. Ann Oncol, 2018, 29(3): 646-653.
|